These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction. Sacks FM. Am J Cardiol; 2008 Dec 22; 102(12A):1L-3L. PubMed ID: 19084082 [No Abstract] [Full Text] [Related]
3. The metabolic syndrome: practical guide to origins and treatment: Part I. Wilson PW, Grundy SM. Circulation; 2003 Sep 23; 108(12):1422-4. PubMed ID: 14504251 [No Abstract] [Full Text] [Related]
4. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. de Simone G, Devereux RB, Chinali M, Best LG, Lee ET, Galloway JM, Resnick HE, Strong Heart Study Investigators. Diabetes Care; 2007 Jul 23; 30(7):1851-6. PubMed ID: 17440172 [Abstract] [Full Text] [Related]
11. gamma-Glutamyltransferase, obesity, physical activity, and the metabolic syndrome in indigenous Australian adults. Li M, Campbell S, McDermott R. Obesity (Silver Spring); 2009 Apr 23; 17(4):809-13. PubMed ID: 19148121 [Abstract] [Full Text] [Related]
12. Obesity and the metabolic syndrome in the elderly--a mini-review. Lechleitner M. Gerontology; 2008 Apr 23; 54(5):253-9. PubMed ID: 18841025 [Abstract] [Full Text] [Related]
13. Obesity: a central risk and cardiovascular target of the cardiometabolic syndrome. Frohlich ED. J Cardiometab Syndr; 2008 Apr 23; 3(3):147-8. PubMed ID: 18983330 [No Abstract] [Full Text] [Related]
14. Nutrition interventions for prevention of type 2 diabetes and the metabolic syndrome. Pittas AG. Nutr Clin Care; 2003 Apr 23; 6(2):79-88. PubMed ID: 14692296 [Abstract] [Full Text] [Related]